AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
14 Marzo 2023 - 9:30PM
Business Wire
AbCellera (Nasdaq: ABCL) today announced two upcoming poster
presentations on its T-cell engager platform at the American
Association for Cancer Research (AACR) Annual Meeting 2023, to be
held at the Orange County Convention Center in Orlando, Florida,
from April 14 to 19.
AbCellera will present the complete characterization of its
panel of differentiated CD3-binding antibodies and demonstrate how
it enables customized design of T-cell engagers for cancer targets.
Additionally, AbCellera will present data on the discovery and
characterization of antibodies against MAGE-A4, a validated
peptide-MHC (pMHC) target for cancer treatment. Together, these two
presentations illustrate how AbCellera’s CD3 panel integrates with
its antibody discovery and development engine to streamline T-cell
engager development.
Details on AbCellera’s poster presentations at AACR are as
follows:
Title: Identifying T-cell engagers with optimal potency
and cytokine-release profiles with a diverse panel of CD3-binding
antibodies Abstract Number: 1886 Date and Time:
Monday, April 17 from 9:00 a.m. to 12:30 p.m. ET
Title: Breaking barriers to access intracellular targets
with T-cell engagers: Discovery of diverse, developable, and
ultra-specific antibodies against a MAGE-A4 pMHC Abstract
Number: 1891 Date and Time: Monday, April 17 from 9:00
a.m. to 12:30 p.m. ET
About AbCellera Biologics Inc. AbCellera searches,
decodes, and analyzes natural immune systems to find antibodies
that its partners can develop into drugs to prevent and treat
disease. AbCellera partners with drug developers of all sizes, from
large pharmaceutical to small biotechnology companies, empowering
them to move quickly, reduce cost, and tackle the toughest problems
in drug development. For more information, please visit
www.abcellera.com
AbCellera Forward-Looking Statements This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
based on management’s current beliefs and assumptions and on
information currently available to management. All statements
contained in this release other than statements of historical fact
are forward-looking statements, including statements regarding our
ability to develop, commercialize and achieve market acceptance of
our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230306005767/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024